WallStreetZenWallStreetZen

NASDAQ: KROS
Keros Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KROS

Based on 8 analysts offering 12 month price targets for Keros Therapeutics Inc

Min Forecast
$15.00+11.19%
Avg Forecast
$20.63+52.89%
Max Forecast
$26.00+92.74%

Should I buy or sell KROS stock?

Based on 8 analysts offering ratings for Keros Therapeutics Inc.

Buy
Strong Buy
3 analysts 37.5%
Buy
2 analysts 25%
Hold
3 analysts 37.5%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KROS's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates KROS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their KROS stock forecasts and price targets.

KROS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-10
lockedlocked$00.00+00.00%2025-05-30
lockedlocked$00.00+00.00%2025-05-12
lockedlocked$00.00+00.00%2025-05-08
lockedlocked$00.00+00.00%2025-04-09
Wells Fargo
Bottom 5%
5
Strong BuyMaintains$26.00+92.74%2025-02-27
Piper Sandler
Bottom 3%
3
Strong BuyMaintains$15.00+11.19%2025-01-17
Wedbush
Top 6%
95
HoldDowngrades$15.00+11.19%2025-01-17

1 of 1

Forecast return on equity

Is KROS forecast to generate an efficient return?

Company
-21.05%
Industry
158.69%
Market
89.3%
KROS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KROS forecast to generate an efficient return on assets?

Company
-19.55%
Industry
40.47%
KROS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KROS earnings per share forecast

What is KROS's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$0.29
Avg 2 year Forecast
-$4.29
Avg 3 year Forecast
-$4.53

KROS revenue forecast

What is KROS's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$219.0M+2%
Avg 2 year Forecast
$26.5M-87.66%
Avg 3 year Forecast
$32.5M-84.86%
KROS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

KROS revenue growth forecast

How is KROS forecast to perform vs Biotechnology companies and vs the US market?

Company
-46.71%
Industry
56.87%
Market
9.9%
KROS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
KROS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

KROS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KROS$13.49$20.63+52.89%Buy
ARVN$7.54$18.71+148.16%Buy
TNGX$5.01$13.00+159.48%Buy
DNA$9.46N/AN/A
TBPH$11.22$21.33+90.13%Strong Buy
View Top Biotech Stocks

Keros Therapeutics Stock Forecast FAQ

Is Keros Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: KROS) stock is to Buy KROS stock.

Out of 8 analysts, 3 (37.5%) are recommending KROS as a Strong Buy, 2 (25%) are recommending KROS as a Buy, 3 (37.5%) are recommending KROS as a Hold, 0 (0%) are recommending KROS as a Sell, and 0 (0%) are recommending KROS as a Strong Sell.

If you're new to stock investing, here's how to buy Keros Therapeutics stock.

What is KROS's earnings growth forecast for 2025-2027?

(NASDAQ: KROS) Keros Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.31%.

Keros Therapeutics's earnings in 2025 is $4,212,000.On average, 9 Wall Street analysts forecast KROS's earnings for 2025 to be -$11,644,439, with the lowest KROS earnings forecast at -$171,803,201, and the highest KROS earnings forecast at $38,178,489. On average, 9 Wall Street analysts forecast KROS's earnings for 2026 to be -$174,150,772, with the lowest KROS earnings forecast at -$246,535,563, and the highest KROS earnings forecast at -$99,913,918.

In 2027, KROS is forecast to generate -$183,813,179 in earnings, with the lowest earnings forecast at -$272,123,274 and the highest earnings forecast at -$117,784,701.

What is KROS's revenue growth forecast for 2025-2027?

(NASDAQ: KROS) Keros Therapeutics's forecast annual revenue growth rate of -46.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.9%.

Keros Therapeutics's revenue in 2025 is $214,713,000.On average, 5 Wall Street analysts forecast KROS's revenue for 2025 to be $8,894,775,666, with the lowest KROS revenue forecast at $8,580,006,208, and the highest KROS revenue forecast at $9,390,283,717. On average, 2 Wall Street analysts forecast KROS's revenue for 2026 to be $1,076,308,471, with the lowest KROS revenue forecast at $528,000,382, and the highest KROS revenue forecast at $1,624,616,560.

In 2027, KROS is forecast to generate $1,320,000,955 in revenue, with the lowest revenue forecast at $609,231,210 and the highest revenue forecast at $2,030,770,700.

What is KROS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: KROS) forecast ROA is -19.55%, which is lower than the forecast US Biotechnology industry average of 40.47%.

What is KROS's Price Target?

According to 8 Wall Street analysts that have issued a 1 year KROS price target, the average KROS price target is $20.63, with the highest KROS stock price forecast at $26.00 and the lowest KROS stock price forecast at $15.00.

On average, Wall Street analysts predict that Keros Therapeutics's share price could reach $20.63 by Jun 10, 2026. The average Keros Therapeutics stock price prediction forecasts a potential upside of 52.89% from the current KROS share price of $13.49.

What is KROS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: KROS) Keros Therapeutics's current Earnings Per Share (EPS) is -$0.12. On average, analysts forecast that KROS's EPS will be -$0.29 for 2025, with the lowest EPS forecast at -$4.23, and the highest EPS forecast at $0.94. On average, analysts forecast that KROS's EPS will be -$4.29 for 2026, with the lowest EPS forecast at -$6.07, and the highest EPS forecast at -$2.46. In 2027, KROS's EPS is forecast to hit -$4.53 (min: -$6.70, max: -$2.90).

What is KROS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: KROS) forecast ROE is -21.05%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.